$0 is the total value of SENZAR ASSET MANAGEMENT, LLC's 1 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 104.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | None | $0 | – | 0 | +100.0% | 0.00% | – | |
| MYL | Exit | MYLAN N Vcall | $0 | – | -2,125 | -100.0% | -0.00% | – |
| PRTA | Exit | PROTHENA CORP PLC | $0 | – | -17,090 | -100.0% | -0.72% | – |
| UTHR | Exit | UNITED THERAPEUTICS CORP DEL | $0 | – | -2,625 | -100.0% | -0.86% | – |
| FOMX | Exit | FOAMIX PHARMACEUTICALS LTD | $0 | – | -67,429 | -100.0% | -0.98% | – |
| PTGX | Exit | PROTAGONIST THERAPEUTICS INC | $0 | – | -61,304 | -100.0% | -1.19% | – |
| TGTX | Exit | TG THERAPEUTICS INC | $0 | – | -31,594 | -100.0% | -1.20% | – |
| ARNA | Exit | ARENA PHARMACEUTICALS INC | $0 | – | -11,123 | -100.0% | -1.40% | – |
| CNCE | Exit | CONCERT PHARMACEUTICALS INC | $0 | – | -29,821 | -100.0% | -1.45% | – |
| ELGX | Exit | ENDOLOGIX INC | $0 | – | -91,422 | -100.0% | -1.49% | – |
| ALNY | Exit | ALNYLAM PHARMACEUTICALS INC | $0 | – | -5,425 | -100.0% | -1.54% | – |
| MDXG | Exit | MIMEDX GROUP INC | $0 | – | -85,050 | -100.0% | -1.57% | – |
| TBPH | Exit | THERAVANCE BIOPHARMA INC | $0 | – | -27,397 | -100.0% | -1.79% | – |
| MCK | Exit | MCKESSON CORP | $0 | – | -7,500 | -100.0% | -2.89% | – |
| ANAB | Exit | ANAPTYSBIO INC | $0 | – | -15,970 | -100.0% | -3.28% | – |
| ALDR | Exit | ALDER BIOPHARMACEUTICALS INC | $0 | – | -85,558 | -100.0% | -3.90% | – |
| AGN | Exit | ALLERGAN PLC | $0 | – | -8,723 | -100.0% | -4.20% | – |
| CVS | Exit | CVS HEALTH CORP | $0 | – | -24,330 | -100.0% | -4.52% | – |
| GILD | Exit | GILEAD SCIENCES INC | $0 | – | -22,300 | -100.0% | -4.56% | – |
| RDUS | Exit | RADIUS HEALTH INC | $0 | – | -60,521 | -100.0% | -5.15% | – |
| REGN | Exit | REGENERON PHARMACEUTICALS | $0 | – | -5,220 | -100.0% | -5.20% | – |
| AZN | Exit | ASTRAZENECA PLCsponsored adr | $0 | – | -71,400 | -100.0% | -7.23% | – |
| CI | Exit | CIGNA CORPORATION | $0 | – | -17,392 | -100.0% | -8.53% | – |
| MYL | Exit | MYLAN N V | $0 | – | -83,370 | -100.0% | -8.69% | – |
| SNY | Exit | SANOFIsponsored adr | $0 | – | -76,836 | -100.0% | -8.87% | – |
| MRK | Exit | MERCK & CO INC | $0 | – | -107,434 | -100.0% | -18.82% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-10-31
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CONCERT PHARMACEUTICALS INC | 16 | Q2 2018 | 4.5% |
| SANOFI | 14 | Q2 2018 | 17.6% |
| CORIUM INTL INC | 14 | Q3 2017 | 2.3% |
| FOAMIX PHARMACEUTICALS LTD | 14 | Q2 2018 | 2.1% |
| RETROPHIN INC | 13 | Q2 2017 | 3.0% |
| ALDER BIOPHARMACEUTICALS INC | 12 | Q2 2018 | 3.9% |
| RIGEL PHARMACEUTICALS INC | 12 | Q3 2016 | 1.8% |
| INSMED INC | 11 | Q3 2017 | 6.2% |
| TEVA PHARMACEUTICAL INDS LTD | 10 | Q1 2016 | 12.3% |
| ORTHOFIX INTL N V | 10 | Q1 2017 | 9.0% |
View SENZAR ASSET MANAGEMENT, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Corium International, Inc.Sold out | February 14, 2018 | 0 | 0.0% |
| Aviragen Therapeutics, Inc. | February 13, 2017 | 1,774,876 | 4.6% |
| CONCERT PHARMACEUTICALS, INC. | February 13, 2017 | 400,588 | 1.8% |
| Foamix Pharmaceuticals Ltd. | February 13, 2017 | 550,997 | 1.5% |
| NEVRO CORPSold out | February 13, 2017 | 0 | 0.0% |
| TIVITY HEALTH, INC. | February 13, 2017 | 383,200 | 1.0% |
| HEALTHWAYS, INC | February 12, 2016 | 2,525,044 | 7.0% |
| Sientra, Inc. | February 12, 2016 | 580,851 | 3.2% |
| Biota Pharmaceuticals, Inc. | January 15, 2016 | 2,025,976 | 5.2% |
View SENZAR ASSET MANAGEMENT, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2018-10-31 |
| 13F-HR | 2018-08-13 |
| 13F-HR | 2018-05-14 |
| SC 13G/A | 2018-02-14 |
| 13F-HR | 2018-02-13 |
| 13F-HR | 2017-11-13 |
| 13F-HR | 2017-08-11 |
| 13F-HR | 2017-05-12 |
| 13F-HR | 2017-02-14 |
| SC 13G/A | 2017-02-13 |
View SENZAR ASSET MANAGEMENT, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.